Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI

靶向肾脏嘌呤信号传导治疗锂诱导的 NDI

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Approximately 20% of the 2 million troops deployed to Iraq and Afghanistan may require treatment for post-traumatic stress disorder (PTSD). Bipolar disorder, a sequel to PTSD is common among Veterans. Currently about 30% of the bipolar Veterans receive chronic lithium (Li) therapy, which also effectively prevents suicidal tendencies. However, chronic usage of lithium is limited by the development of nephrogenic diabetes insipidus (NDI), a condition in which the kidneys cannot concentrate urine resulting in excessive loss of water and electrolytes. Currently used modalities for the treatment of NDI are encountered with varying degrees of success as well as side effects. Refinement and/or replacement of the current side effect-prone therapies with new drugs based on an improved understanding of molecular pathophysiology of Li-induced NDI should result in improved efficacy and fewer side effects. In this context, we discovered that a signaling system, called purinergic signaling, can be targeted to ameliorate Li-induced NDI. The goal of this project is to decipher the role of ADP-activated P2Y12 receptor (R) in Li- induced NDI. This will have significant impact on our current knowledge of pathophysiology of Li-induced NDI, with a potential for the development of novel therapies. We observed that P2Y12-R is expressed in the kidney, and its selective blockade by clopidogrel bisulfate (Plavix(r)), a widely used anti-clotting drug, increases the ability of the kidney to conserve water, and ameliorates Li-induced NDI. Based on these novel observations, we hypothesize that blockade of P2Y12-R ameliorates Li-induced NDI by re- sensitizing the kidney collecting duct to the action of AVP. We further hypothesize that P2Y12-R blockade suppresses Li-induced increases in prostanoid and nitric oxide production, and oxidative stress, thus contributing to overall beneficial effect. To address this hypothesis, we propose three specific aims, and use rat and mouse models, cultured kidney collecting duct cells, and agents that modulate signaling through for P2Y12R. Aim # 1 is to investigate the effect of P2Y12-R on Li-induced decrease in APQ2 expression in the collecting duct and the potential mechanisms involved in it. Aim # 2 is to investigate the beneficial effects of P2Y12-R blockade on Li-induced increases in prostanoid and nitric oxide production and oxidative stress. Aim # 3 is to evaluate the therapeutic benefits of targeting P2Y12-R (with or without concurrent blunting of P2Y2-R) on Li-induced NDI, collecting duct remodeling and cell proliferation in the kidney. Thus, this proposal is based on a novel concept, observations, and hypothesis, and it shifts the current focus of research and therapies for Li-induced NDI from predominantly the ones that counter anti- AVP effects to the ones that enhance the sensitivity of the kidney to AVP, thereby ensuing minimal side effects.
 描述(由申请人提供): 在部署到伊拉克和阿富汗的200万军队中,大约20%的人可能需要治疗创伤后应激障碍(PTSD)。双相情感障碍是创伤后应激障碍的一种,在退伍军人中很常见。目前,约30%的双相退伍军人接受慢性锂(Li)治疗,这也有效地防止自杀倾向。然而,锂的长期使用受到肾源性尿崩症(NDI)发展的限制,这是一种肾脏无法浓缩尿液导致水和电解质过度流失的疾病。目前用于治疗NDI的方式遇到了不同程度的成功以及副作用。基于对Li诱导的NDI的分子病理生理学的更好理解,用新药改进和/或替代目前的副作用倾向性疗法应导致改善的疗效和更少的副作用。在这种情况下,我们发现,信号系统,称为嘌呤信号,可以有针对性地改善锂诱导的NDI。本项目的目标是破译ADP激活的P2 Y12受体(R)在Li诱导的NDI中的作用。这将对我们目前对锂诱导NDI的病理生理学的认识产生重大影响,并有可能开发新的治疗方法。我们观察到,P2 Y12-R在肾脏中表达,并且其被广泛使用的抗凝药物硫酸氢氯吡格雷(Plaidogrel(r))选择性阻断,增加肾脏保存水的能力,并改善Li诱导的NDI。基于这些新的观察结果,我们假设阻断P2 Y12-R通过使肾集合管对AVP的作用重新敏感来改善Li诱导的NDI。我们进一步假设,P2 Y12-R阻断抑制锂诱导的前列腺素和一氧化氮产生的增加,以及氧化应激,从而有助于整体有益的效果。为了解决这一假设,我们提出了三个具体的目标,并使用大鼠和小鼠模型,培养的肾集合管细胞,和代理商,通过P2 Y12 R调节信号。目的1研究P2 Y12-R对锂诱导的集合管APQ 2表达降低的影响及其可能的机制,目的2研究P2 Y12-R阻断对锂诱导的前列腺素和一氧化氮产生增加和氧化应激的有益作用。目的#3是评估靶向P2 Y12-R(伴随或不伴随P2 Y2-R的钝化)对肾脏中Li诱导的NDI、集合管重塑和细胞增殖的治疗益处。因此,该提议基于新的概念、观察和假设,并且其将Li诱导的NDI的研究和治疗的当前焦点从主要对抗抗AVP作用的那些转移到增强肾脏对AVP的敏感性的那些,从而确保最小的副作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BELLAMKONDA K KISHORE其他文献

BELLAMKONDA K KISHORE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BELLAMKONDA K KISHORE', 18)}}的其他基金

Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    8195888
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    7931303
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    8397534
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    8259070
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    9907855
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Potential Therapeutic Applications of Ecto-Nucleotidases in Lithium-induced NDI
外切核苷酸酶在锂诱导 NDI 中的潜在治疗应用
  • 批准号:
    7878061
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    8921910
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Potential Therapeutic Applications of Ecto-Nucleotidases in Lithium-induced NDI
外切核苷酸酶在锂诱导 NDI 中的潜在治疗应用
  • 批准号:
    7660114
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
  • 批准号:
    9040769
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
P2U(P2Y2)-PURINOCEPTOR AND WATER TRANSPORT IN RAT KIDNEY
P2U(P2Y2)-嘌呤受体和大鼠肾脏中的水转运
  • 批准号:
    6517989
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Neuroendocrine regulation of energy metabolism: role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the thermoregulatory cascade
能量代谢的神经内分泌调节:垂体腺苷酸环化酶激活多肽(PACAP)在温度调节级联中的作用
  • 批准号:
    RGPIN-2021-04040
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
Controlled Release of Pituitary Adenylate Cyclase Activating Polypeptide from a Hydrogel-Nanoparticle Delivery Vehicle for Applications in the Central Nervous System
从水凝胶-纳米粒子递送载体中控制释放垂体腺苷酸环化酶激活多肽,用于中枢神经系统的应用
  • 批准号:
    547124-2020
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Controlled Release of Pituitary Adenylate Cyclase Activating Polypeptide from a Hydrogel-Nanoparticle Delivery Vehicle for Applications in the Central Nervous System
从水凝胶-纳米粒子递送载体中控制释放垂体腺苷酸环化酶激活多肽,用于中枢神经系统的应用
  • 批准号:
    547124-2020
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Neuroendocrine regulation of energy metabolism: role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the thermoregulatory cascade
能量代谢的神经内分泌调节:垂体腺苷酸环化酶激活多肽(PACAP)在温度调节级联中的作用
  • 批准号:
    RGPIN-2021-04040
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
The Molecular Mechanism of the Secretion of the Bacterial Toxin Adenylate Cyclase
细菌毒素腺苷酸环化酶分泌的分子机制
  • 批准号:
    451966
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10455587
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10261394
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Diagnosis and therapeutic effect of neurally mediated syncope (NMS) using fluctuation of adenylate cyclase activity
利用腺苷酸环化酶活性波动对神经介导性晕厥(NMS)的诊断和治疗效果
  • 批准号:
    20K08498
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pituitary adenylate cyclase-activating polypeptide 27 in the paraventricular thalamus and its projections: Role in ethanol drinking
室旁丘脑中的垂体腺苷酸环化酶激活多肽 27 及其预测:在乙醇饮用中的作用
  • 批准号:
    10380126
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10662279
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了